187 related articles for article (PubMed ID: 32409678)
1. N-Terminal guanidine derivatives of teicoplanin antibiotics strongly active against glycopeptide resistant Enterococcus faecium.
Szűcs Z; Bereczki I; Rőth E; Milánkovits M; Ostorházi E; Batta G; Nagy L; Dombrádi Z; Borbás A; Herczegh P
J Antibiot (Tokyo); 2020 Sep; 73(9):603-614. PubMed ID: 32409678
[TBL] [Abstract][Full Text] [Related]
2. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
3. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.
Malabarba A; Ciabatti R; Scotti R; Goldstein BP; Ferrari P; Kurz M; Andreini BP; Denaro M
J Antibiot (Tokyo); 1995 Aug; 48(8):869-83. PubMed ID: 7592033
[TBL] [Abstract][Full Text] [Related]
4. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
Kirk M; Hill RL; Casewell MW; Beighton D
Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
[No Abstract] [Full Text] [Related]
5. Influence of VanD type resistance on activities of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecium.
Lefort A; Garry L; Depardieu F; Courvalin P; Fantin B
Antimicrob Agents Chemother; 2003 Nov; 47(11):3515-8. PubMed ID: 14576110
[TBL] [Abstract][Full Text] [Related]
6. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
7. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium.
Fantin B; Leclercq R; Arthur M; Duval J; Carbon C
Antimicrob Agents Chemother; 1991 Aug; 35(8):1570-5. PubMed ID: 1834013
[TBL] [Abstract][Full Text] [Related]
8. Resistance of enterococci to ampicillin and glycopeptide antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance.
Fontana R; Ligozzi M; Mazzariol A; Veneri G; Cornaglia G
Clin Infect Dis; 1998 Aug; 27 Suppl 1():S84-6. PubMed ID: 9710675
[TBL] [Abstract][Full Text] [Related]
9. Occurrence and spread of antibiotic resistances in Enterococcus faecium.
Klare I; Konstabel C; Badstübner D; Werner G; Witte W
Int J Food Microbiol; 2003 Dec; 88(2-3):269-90. PubMed ID: 14597000
[TBL] [Abstract][Full Text] [Related]
10. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
11. vanA-targeted oligonucleotide DNA probe designed to monitor vancomycin- and teicoplanin-resistant bacteria in surface waters.
Nakipoglu M; Yilmaz F; Icgen B
Environ Monit Assess; 2016 Oct; 188(10):569. PubMed ID: 27640164
[TBL] [Abstract][Full Text] [Related]
12. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
[TBL] [Abstract][Full Text] [Related]
13. [Antibiotic susceptibility analysis of Enterococcus spp. isolated from urine].
Rudy M; Nowakowska M; Wiechuła B; Zientara M; Radosz-Komoniewska H
Przegl Lek; 2004; 61(5):473-6. PubMed ID: 15515808
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
15. In-vitro study of the synergy between beta-lactam antibiotics and glycopeptides against enterococci.
Ravizzola G; Cabibbo E; Peroni L; Longo M; Pollara PC; Corulli M; Pizzi R; Dima F; Fallacara C; Turano A
J Antimicrob Chemother; 1997 Apr; 39(4):461-70. PubMed ID: 9145818
[TBL] [Abstract][Full Text] [Related]
16. Glycopeptide resistance in enterococci.
Méndez-Alvarez S; Pérez-Hernández X; Claverie-Martín F
Int Microbiol; 2000 Jun; 3(2):71-80. PubMed ID: 11001535
[TBL] [Abstract][Full Text] [Related]
17. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
18. [A 6-year study of glycopeptides-resistant enterococci in 3 intensive care units of the University Hospital of Montpellier].
Godreuil S; Marchandin H; Boulier A; Boumzebra A; Campos J; Jean-Pierre H
Pathol Biol (Paris); 2007 Nov; 55(8-9):418-23. PubMed ID: 17905540
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype.
Song JH; Ko KS; Suh JY; Oh WS; Kang CI; Chung DR; Peck KR; Lee NY; Lee WG
J Antimicrob Chemother; 2008 Apr; 61(4):838-44. PubMed ID: 18230690
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and study of antibacterial activities of antibacterial glycopeptide antibiotics conjugated with benzoxaboroles.
Printsevskaya SS; Reznikova MI; Korolev AM; Lapa GB; Olsufyeva EN; Preobrazhenskaya MN; Plattner JJ; Zhang YK
Future Med Chem; 2013 Apr; 5(6):641-52. PubMed ID: 23617428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
